Preconception antiphospholipid antibodies and risk of subsequent early pregnancy loss

Abstract

Objectives

To prospectively estimate the association of preconception antiphospholipid antibodies (aPL) with subsequent pregnancy loss using a cohort design. aPL have been associated with recurrent early pregnancy loss (EPL) prior to 10 weeks in previous case-control studies. Prospective ascertainment of pregnancy loss is challenging, as most women do not seek care prior to EPL.

Methods

Secondary analysis of the Effects of Aspirin in Gestation and Reproduction trial of preconception low-dose aspirin. Preconception anticardiolipin (aCL) and anti-β2-glycoprotein-I (a-β2-I) were assessed in 1208 women with one or two prior pregnancy losses and no more than two prior live births. Comparison cohorts were defined by positive aPL (+aPL) or negative aPL (–aPL) status. All women were followed for six menstrual cycles while trying to conceive; if successful, they underwent an ultrasound at 6–7 weeks’ gestation. EPL was defined as loss prior to 10 weeks’ gestation; embryonic loss was loss after visualization of an embryo but prior to 10 weeks; clinical loss was any loss after visualization of an embryo (with or without fetal cardiac activity detected).

Results

In total, 14/1208 (1%) tested positive for +aPL. 786/1208 (65%) women had positive human chorionic gonadotropin during the study period, of which 9/786 (1%) had +aPL. Of the 786 pregnant women, 589 (75%) had live births and 24% had pregnancy losses. Women with +aPL experienced EPL at similar rates as women with –aPL, 44% vs 21% (aRR 2.4, 95% confidence interval (CI) 0.5–10.9). Embryonic loss was more common in women with +aCL IgM (aRR 4.8, 95% CI 1.0–23.0) and in women with two positive aPL. Clinical pregnancy loss was more common in women with positive a-β2-I IgM (50% vs 16.5%, aRR 3.7, 95% CI 1.3–10.8).

Conclusion

Positive levels of aPL are rare in women with one or two prior pregnancy losses and are not clearly associated with an increased rate of subsequent loss.

Clinical trial registration

The original source study was registered at ClinicalTrials.gov (#NCT00467363).

Keywords

Anticardiolipin antibodies antiphospholipid syndrome pregnancy

Get full access to this article

View all access options for this article.

References

Branch

Gibson

Silver

. Recurrent miscarriage. N Engl J Med 2010; 363: 1740–1747.

Kwak-Kim

Agcaoili

Aleta

et al.

Management of women with recurrent pregnancy losses and antiphospholipid antibody syndrome. Am J Reprod Immunol 2013; 69: 596–607.

Silver

Parker

Reddy

et al.

Antiphospholipid antibodies in stillbirth. Obstet Gynecol 2013; 122: 641–657.

Miyakis

Lockshin

Atsumi

et al.

International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295–306.

Abou-Nassar

Carrier

Ramsay

Rodger

. The association between antiphospholipid antibodies and placenta mediated complications: A systematic review and meta-analysis. Thromb Res 2011; 128: 77–85.

Clark

Laskin

Spitzer

. Anticardiolipin antibodies and recurrent early pregnancy loss: A century of equivocal evidence. Hum Reprod Update 2012; 18: 474–484.

de Jesus

Agmon-Levin

Andrade

et al.

14th International Congress on Antiphospholipid Antibodies Task Force report on obstetric antiphospholipid syndrome. Autoimmun Rev 2014; 13: 795–813.

Infante-Rivard

David

Gauthier

Rivard

G-E

. Lupus anticoagulants, anticardiolipin antibodies, and fetal loss. N Engl J Med 1991; 325: 1063–1066.

Schisterman

Cole

Platt

. Accuracy loss due to selection bias in cohort studies with left truncation. Paediatr Perinat Epidemiol 2013; 27: 491–502.

10.

Chauleur

Galanaud

Alonso

et al.

Observational study of pregnant women with a previous spontaneous abortion before the 10th gestation week with and without antiphospholipid antibodies. J Thromb Haemost 2010; 8: 699–706.

11.

Schisterman

Silver

Lesher

et al.

Preconception low-dose aspirin and pregnancy outcomes: Results from the EAGeR randomised trial. Lancet 2014; 384: 29–36.

12.

Schisterman

Silver

Perkins

et al.

A randomised trial to evaluate the effects of low-dose aspirin in gestation and reproduction: Design and baseline characteristics. Paediatr Perinat Epidemiol 2013; 27: 598–609.

13.

Mumford

Silver

Sjaarda

et al.

Expanded findings from a randomized controlled trial of preconception low-dose aspirin and pregnancy loss. Hum Reprod 2016; 31: 657–665.

14.

Kramer

Platt

Wen

et al.

A new and improved population-based Canadian reference for birth weight for gestational age. Pediatrics 2001; 108: E35–E35.

15.

Robins

Hernan

Brunback

. Marginal structural models and causal inference in epidemiology. Epidemiology 2000; 11: 550–560.

16.

Hernán

Hernández-Díaz

Robins

. A Structural approach to selection bias. Epidemiology 2004; 15: 615–625.

17.

Opatrny

David

Kahn

Shrier

Rey

. Association between antiphospholipid antibodies and recurrent fetal loss in women without autoimmune disease: A metaanalysis. J Rheumatol 2006; 33: 2214–2221.

18.

Matsubayashi

Sugi

Arai

et al.

Different antiphospholipid antibody specificities are found in association with early repeated pregnancy loss versus recurrent IVF-failure patients. Am J Reprod Immunol 2001; 46: 323–329.

19.

Bowman

Wunsche

Porter

Silver

Branch

. Prevalence of antiphospholipid antibodies and risk of subsequent adverse obstetric outcomes in women with prior pregnancy loss. J Reprod Immunol 2015; 107: 59–63.

20.

Clark

Davidovits

Spitzer

Laskin

. The lupus anticoagulant: Results from 2257 patients attending a high-risk pregnancy clinic. Blood 2013; 122: 341–347. quiz 466.

21.

Roque

Paidas

Funai

Kuczynski

Lockwood

. Maternal thrombophilias are not associated with early pregnancy loss. Thromb Haemost 2004; 91: 290–295.

22.

Wald

Hackshaw

Frost

. When can a risk factor be used as a worthwhile screening test? BMJ 1999; 319: 1562–1555.